Akorn, Inc. has added two injectable drug products to its API supply and margin sharing agreement with Natco Pharma. The two ANDA drug products are indicated for the prevention of nausea and vomiting associated with cancer chemotherapy.

Under the agreement, signed April 2006, Natco will be responsible for the supply of API for both drug products and Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the U.S. and Canada.

Arthur S. Przybyl, Akorn's president and chief executive officer, stated, "We are excited to expand our business partnership with Natco Pharma. These two products will provide an excellent fit with our oncology product pipeline."

Rejeev Nannapaneni, Natco Pharma's chief operating officer, stated, "We are happy to take our cooperation to four projects now. This deal structure will enhance business opportunities in an increasingly competitive environment."